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TNF-induced apoptosis is tightly regulated by the 
NF-κB  pathway.  Under  physiologic  conditions,  TNFα 
stimulation induces NF-κB activation and cell survival, 
due to the regulation of anti-apoptotic genes, including 
c-FLIP,  a  caspase-8  inhibitor,  whose  expression  is 
sufficient to protect cells against TNF-induced apoptosis. 
TNF triggers cell death only in circumstances where the 
NF-κB pathway is defective. Rushworth and collaborators 
have  recently  demonstrated,  however,  that  the  heme 
oxygenase-1 (HO-1), also known as Heat shock protein 
32 (Hsp32) [1], like c-FLIP, can afford protection against 
TNF-induced  cell  death  in AML  cells,  despite  NF-κB 
inactivation [2]. They now provide evidence that TNF 
mediated HO-1 up-regulation, is negatively regulated by 
c-FLIP, revealing a novel negative regulatory feedback 
loop controlling apoptosis induced by TNRI (Figure 1).
In contrast to Fas or TRAIL receptor-mediated cell 
death, apoptosis induced by TNFRI is a two-step process 
that requires the formation of two sequential signalling 
complexes [3].  The plasma membrane-bound complex 
I,  including  TNFR1,  TRADD,  RIP1  and  TRAF2,  is 
Figure 1: Contribution of HO-1 and c-FLIPL to the regulation of  TNF signalling in monocytes and acute myeloid leukemia 
cells (AML). (A) In monocytes, engagement of TNFR1 by TNFα induces activation of NF-κB, leading to up-regulation of FLIP and inhibition 
of cell death, however inactivation of NF-κB (B) prevents FLIP neosynthesis, allowing caspase activation and apoptosis. (C) AML cells are 
resistant to TNFα-induced apoptosis, even upon inactivation of NF- κB (D), due to the up-regulation of HO-1. (E) Simultaneous inactivation 
of c-FLIP and HO-1 enhances TNF-induced cell death.
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dedicated to the activation of the survival pathway NF-
κB. FADD and caspase-8 are recruited in the “cytosolic” 
complex,  also  coined  complex  II,  which  is  devoid  of 
TNFRI, triggering caspase-8 activation and apoptosis [3]. 
In the vast majority of cells, however, activation of NF-
κB induces protection against TNF-induced cell death [4]. 
Several anti-apoptotic genes are regulated by NF-κB [5], 
but so far only c-FLIP has been demonstrated to afford 
full protection when expressed alone [6,7]. Activation of 
complex II and thus triggering of the apoptotic program is 
generally thought to occur in NF-κB defective cells due to 
the lack of c-FLIP supply [8]. 
  HO-1  is  a  stress-related  anti-apoptotic  molecule 
that has been implicated in enhanced survival of cancer 
cells and in drug-resistance [1]. Overexpression of HO-1 
protects cells from H2O2-, Fas- or TNF-induced apoptosis 
[9-11].  Unlike HO-2, the second evolutionary conserved 
heme  oxygenase  isoenzyme,  HO-1  is  not  expressed 
constitutively. HO-1 is generally induced under oxidative 
stress enabling enhanced free heme catabolism and 
inhibition of programmed cell death[1]. HO-1 mediated 
cytoprotection has been assigned to the heme catabolism 
sub-product Fe2+, which triggers reactive oxygen species 
(ROS)  production  and  NF-κB  activation  [12].  Induced 
expression of HO-1 by IL-1 and TNFα was suggested to 
involve protein kinase c, calcium and phospholipase A2 
[13]. Activation of the PkB/Akt pathway and induction 
of Nrf2 were shown to induce HO-1 up-regulation upon 
H2O2 stimulation[9]. More recently it was shown that 
TNF-mediated  ROS  production,  in  NF-κB  inactivated 
AML  cells,  induced  the  activation  of  the  transcription 
factor  Nrf2  leading  to  HO-1  up-regulation  [2].  The 
cytoprotective activity of HO-1 in endothelial cells was 
demonstrated to require NF-κB activation by TNFα [14]. 
Interestingly, HO-1-mediated inhibition of TNFRI-induced 
apoptosis, in NF-κB defective cells, can be restored by the 
ectopic expression of some NF-κB regulated genes such 
as c-IAP2, A1 or A20 [14]. Furthermore, HO-1-mediated 
protection against TNF-induced cell death is not restricted 
to tumour cells, as endothelial cells or human fibroblasts 
induced to express HO-1 fail to undergo apoptosis [14,15].
Remarkably,  and  in  contrast  to  most  studies 
demonstrating  that  inhibition  of  the  NF-κB  pathway 
restores TNF-induced cell death in normal and cancer 
cells, Rushworth et al. demonstrate in this issue that NF-κB 
inhibition only affords partial restoration of apoptosis in 
AML cells, due to the up-regulation of HO-1. Accordingly, 
inactivation  of  c-FLIPL  expression  was  sufficient  to 
trigger the accumulation of HO-1 in the absence of TNF, 
though apoptosis following TNFα stimulation was only 
partially  restored. Accordingly,  inactivation  of  c-FLIPL 
expression in these cells, albeit partially restoring TNFα-
induced  apoptosis,    in  the  absence  of  TNF,  triggered 
the  accumulation  of  HO-1.  However,  simultaneous 
inactivation of c-FLIPL and HO-1 significantly enhanced 
AML cell sensitivity to TNFα. Rushworth et al. make the 
critical  observation  that  induction  of  HO-1  expression 
is  negatively  regulated  at  the  steady  state  by  c-FLIPL, 
but not the short forms of c-FLIP, providing a plausible 
explanation  for  the  resistance  of  AML  cells  to  TNF-
induced  apoptosis,  despite  inactivation  of  the  NF-κB 
pathway.
These  results  demonstrate  that  HO-1  exerts 
cytoprotection  in  AML  cells,  irrespective  of  NF-κB 
activation, and suggest in addition that HO-1 and c-FLIPL 
may negatively regulate TNF-induced cell death in a non-
redundant, but exclusive manner. Of particular interest, 
c-FLIPL down-regulation  was  unable  to  promote  HO-1 
expression in monocytes. Thus the markedly increased 
expression of c-FLIPL and the constitutive activation of 
NF-κB in erythroleukemia cells [16] would support the 
proposal that negative regulation of HO-1 expression by 
c-FLIPL, at the basal level, might require sustained NF-
κB activation. In line with this hypothesis, it has been 
demonstrated in the past that over-expression of c-FLIP, or 
at least its amino acid terminal portion, could induce NF-
κB activation [17-20]. It is not clear, however, whether 
NF-κB  activation  alone  is  sufficient  to  repress  HO-1. 
ROS  production,  through  the  activation  of  Nrf2,  may 
also induce the restoration of HO-1 expression in cells 
in which c-FLIPL has been inactivated, as c-FLIP down-
regulation was shown to induce ROS production in some 
tumour cells [21], while its over-expression produces the 
opposite effect [22]. 
While it is clear that the molecular mechanisms 
underlying c-FLIPL-mediated HO-1 repression at the basal 
level needs to be explored more precisely, the possibility 
that HO-1 itself may regulate c-FLIP expression, through 
its ability to inhibit NF-κB activation, or to induce ROS 
remains an open question. In line with this hypothesis, 
it has recently been demonstrated that HO-1 was able to 
impair  NF-κB  nuclear  translocation  in  cardiomyocytes 
[23] and that ROS production can trigger the degradation 
of  c-FLIP  in  an  ubiquitylation-dependent  manner  [24]. 
Mutual regulation of these cellular “safeguards” would 
thus certainly be beneficial for tumour cells to maintain 
a high level of protection against TNF-induced killing. 
Altogether these findings uncover a novel cell-decision 
regulatory mechanism controlling cell death signalling 
induced  by TNFRI,  which  may  extend  to  other  death-
inducing ligands of the TNF family.  
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